Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 1
2002 1
2006 1
2009 3
2010 3
2011 3
2013 2
2014 1
2015 1
2016 5
2017 1
2018 1
2019 3
2020 1
2021 1
2022 3
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis and treatment of von Willebrand disease in 2024 and beyond.
James P, Leebeek F, Casari C, Lillicrap D. James P, et al. Haemophilia. 2024 Apr;30 Suppl 3:103-111. doi: 10.1111/hae.14970. Epub 2024 Mar 13. Haemophilia. 2024. PMID: 38481079 Review.
MANUSCRIPT BACKGROUND AND AIM: The diagnosis and clinical care of patients with von Willebrand disease (VWD) has continued to evolve since the characterization of the von Willebrand factor (VWF) gene in 1985. ...
MANUSCRIPT BACKGROUND AND AIM: The diagnosis and clinical care of patients with von Willebrand disease (VWD) has continued to evolve …
von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.
Lillicrap D. Lillicrap D. Hematology Am Soc Hematol Educ Program. 2013;2013:254-60. doi: 10.1182/asheducation-2013.1.254. Hematology Am Soc Hematol Educ Program. 2013. PMID: 24319188 Review.
Finally, a new recombinant VWF concentrate has just completed clinical trial evaluation and has demonstrated excellent hemostatic efficacy and safety....
Finally, a new recombinant VWF concentrate has just completed clinical trial evaluation and has demonstrated excellent hemosta …
Sixth Åland Island Conference on von Willebrand disease.
Berntorp E, Trakymienė SS, Federici AB, Holstein K, Corrales-Medina FF, Pierce GF, Srivastava A, Prondzinski MVD, Johnsen JM, Zupan IP, Halimeh S, Nummi V, Roberts JC. Berntorp E, et al. Haemophilia. 2022 Jul;28 Suppl 5(Suppl 5):3-15. doi: 10.1111/hae.14495. Haemophilia. 2022. PMID: 35861919 Free PMC article.
AIM: The meeting brought together experts in the field of VWD from around the world to share the latest advances and knowledge in VWD. RESULTS AND DISCUSSION: The topics covered both clinical aspects of disease management, and biochemical and laboratory insights into the d …
AIM: The meeting brought together experts in the field of VWD from around the world to share the latest advances and knowledge in VWD. RESUL …
Prophylaxis in von Willebrand Disease: Coming of Age?
Saccullo G, Makris M. Saccullo G, et al. Semin Thromb Hemost. 2016 Jul;42(5):498-506. doi: 10.1055/s-0036-1581106. Epub 2016 Jun 2. Semin Thromb Hemost. 2016. PMID: 27253087 Free article. Review.
An evaluation of von Willebrand factor (recombinant) therapy for adult patients living with severe type 3 von Willebrand disease.
Hancock JM, Escobar MA. Hancock JM, et al. Expert Rev Hematol. 2023 Mar;16(3):157-161. doi: 10.1080/17474086.2023.2184339. Epub 2023 Mar 2. Expert Rev Hematol. 2023. PMID: 36861346 Review.
More recently, however, the FDA has approved rVWF for routine prophylaxis to prevent bleeding episodes for those patients with severe type 3 VWD receiving on-demand therapy. AREAS COVERED: This review will focus on recent phase III trial results from NCT02973087 regarding …
More recently, however, the FDA has approved rVWF for routine prophylaxis to prevent bleeding episodes for those patients with severe type 3 …
Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3.
Berntorp E. Berntorp E. Semin Thromb Hemost. 2006 Sep;32(6):621-5. doi: 10.1055/s-2006-949667. Semin Thromb Hemost. 2006. PMID: 16977572 Review.
We conclude that long-term prophylactic treatment of vWD is warranted in the majority of cases with type 3 and in some cases, depending on the clinical phenotype, for patients with other subtypes. Additional studies are ongoing in an international effort, the von Willebran …
We conclude that long-term prophylactic treatment of vWD is warranted in the majority of cases with type 3 and in some cases, depending on t …
Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial.
Leebeek FWG, Peyvandi F, Tiede A, Castaman G, Escobar M, Wang M, Zülfikar B, Susen S, Miesbach W, Wang S, Wang Y, Zhang J, Özen G. Leebeek FWG, et al. Eur J Haematol. 2023 Jul;111(1):29-40. doi: 10.1111/ejh.13949. Epub 2023 Apr 11. Eur J Haematol. 2023. PMID: 36823994 Clinical Trial.
OBJECTIVES: To describe efficacy/safety of recombinant von Willebrand factor (rVWF) prophylaxis in patients with type 3 von Willebrand disease (VWD). METHODS: This post hoc analysis of a phase 3 open-label trial provides a more detailed analysis of adults with type 3 VWD, …
OBJECTIVES: To describe efficacy/safety of recombinant von Willebrand factor (rVWF) prophylaxis in patients with type 3 von Willebrand disea …
33 results